Literature DB >> 25569708

Improved memory for reward cues following acute buprenorphine administration in humans.

Supriya Syal1, Jonathan Ipser2, David Terburg3, Mark Solms4, Jaak Panksepp5, Susan Malcolm-Smith4, Peter A Bos3, Estrella R Montoya3, Dan J Stein2, Jack van Honk6.   

Abstract

In rodents, there is abundant evidence for the involvement of the opioid system in the processing of reward cues, but this system has remained understudied in humans. In humans, the happy facial expression is a pivotal reward cue. Happy facial expressions activate the brain's reward system and are disregarded by subjects scoring high on depressive mood who are low in reward drive. We investigated whether a single 0.2mg administration of the mixed mu-opioid agonist/kappa-antagonist, buprenorphine, would influence short-term memory for happy, angry or fearful expressions relative to neutral faces. Healthy human subjects (n38) participated in a randomized placebo-controlled within-subject design, and performed an emotional face relocation task after administration of buprenorphine and placebo. We show that, compared to placebo, buprenorphine administration results in a significant improvement of memory for happy faces. Our data demonstrate that acute manipulation of the opioid system by buprenorphine increases short-term memory for social reward cues.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Happy facial expression; Opioids; Reward; Short term memory

Mesh:

Substances:

Year:  2014        PMID: 25569708     DOI: 10.1016/j.psyneuen.2014.11.009

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  10 in total

1.  Effects of buprenorphine on responses to social stimuli in healthy adults.

Authors:  Anya K Bershad; Jacob A Seiden; Harriet de Wit
Journal:  Psychoneuroendocrinology       Date:  2015-09-12       Impact factor: 4.905

Review 2.  μ opioid receptor, social behaviour and autism spectrum disorder: reward matters.

Authors:  Lucie P Pellissier; Jorge Gandía; Thibaut Laboute; Jérôme A J Becker; Julie Le Merrer
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

3.  Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.

Authors:  Amanda B Namchuk; Irwin Lucki; Caroline A Browne
Journal:  Adv Drug Alcohol Res       Date:  2022-02-21

4.  Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors.

Authors:  Edgardo Falcon; Caroline A Browne; Rosa M Leon; Vanessa C Fleites; Rachel Sweeney; Lynn G Kirby; Irwin Lucki
Journal:  Neuropsychopharmacology       Date:  2016-03-16       Impact factor: 7.853

Review 5.  Considering the context: social factors in responses to drugs in humans.

Authors:  Harriet de Wit; Michael Sayette
Journal:  Psychopharmacology (Berl)       Date:  2018-02-22       Impact factor: 4.530

Review 6.  Neuroendocrine models of social anxiety disorder.

Authors:  Jack van Honk; Peter A Bos; David Terburg; Sarah Heany; Dan J Stein
Journal:  Dialogues Clin Neurosci       Date:  2015-09       Impact factor: 5.986

7.  Understanding the Neurocomputational Mechanisms of Antidepressant Placebo Effects.

Authors:  Marta Peciña; Alexandre Y Dombrovski; Rebecca Price; Helmet T Karim
Journal:  J Psychiatr Brain Sci       Date:  2021-02-15

8.  The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report.

Authors:  Charlotte Skoglund; Siri Leknes; Markus Heilig
Journal:  J Med Case Rep       Date:  2022-04-15

9.  Effects of Buprenorphine on Responses to Emotional Stimuli in Individuals with a Range of Mood Symptomatology.

Authors:  Anya K Bershad; Nicholas A Ruiz; Harriet de Wit
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

Review 10.  The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies.

Authors:  Isabell M Meier; Marie Eikemo; Siri Leknes
Journal:  Curr Addict Rep       Date:  2021-04-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.